News & Updates

Mental health risks associated with cannabis use disorder (CUD) differ by age and comorbid substance use disorders (SUDs), suggests a study.

BTK inhibition with rilzabrutinib does not appear to significantly decrease the incidence of loss-of-asthma-control (LOAC) event compared with placebo in patients with moderate-to-severe asthma with uncontrolled symptoms, according to a phase II study. However, the investigational drug has been associated with meaningful symptom improvements over time, despite withdrawal of background therapy.

Interleukin (IL)-6 inhibition with vamikibart is safe and well tolerated and helps improve clinical outcomes in patients with uveitic macular edema (UME), as shown in the phase I DOVETAIL nonrandomized clinical trial.

A hybrid obesity care that combines physician-directed glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment and lifestyle coaching via a mobile health app yields meaningful and sustained improvements in weight and metabolic parameters in a real-world setting, as shown in a local study.

The oral JAK1 inhibitor povorcitinib elicits clinical response in the subpopulation of hidradenitis suppurativa (HS) patients who had prior treatment with anti-TNF, according to pooled 24-week data from the phase III STOP-HS trials.

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.